JP2021518170A5 - - Google Patents
Info
- Publication number
- JP2021518170A5 JP2021518170A5 JP2021500367A JP2021500367A JP2021518170A5 JP 2021518170 A5 JP2021518170 A5 JP 2021518170A5 JP 2021500367 A JP2021500367 A JP 2021500367A JP 2021500367 A JP2021500367 A JP 2021500367A JP 2021518170 A5 JP2021518170 A5 JP 2021518170A5
- Authority
- JP
- Japan
- Prior art keywords
- hgfr
- human
- antibody fragment
- fusion protein
- extracellular
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000003875 | 2018-03-22 | ||
| IT102018000003875A IT201800003875A1 (it) | 2018-03-22 | 2018-03-22 | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| PCT/IB2019/052307 WO2019180658A1 (en) | 2018-03-22 | 2019-03-21 | Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518170A JP2021518170A (ja) | 2021-08-02 |
| JPWO2019180658A5 JPWO2019180658A5 (https=) | 2022-02-22 |
| JP2021518170A5 true JP2021518170A5 (https=) | 2022-02-22 |
| JP7381555B2 JP7381555B2 (ja) | 2023-11-15 |
Family
ID=62530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500367A Active JP7381555B2 (ja) | 2018-03-22 | 2019-03-21 | 腫瘍および／または転移の治療のための抗－ｈｇｆｒ抗体およびｈｅｇｆｒの組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11814433B2 (https=) |
| EP (1) | EP3768710A1 (https=) |
| JP (1) | JP7381555B2 (https=) |
| KR (1) | KR20200135449A (https=) |
| CN (1) | CN112041340A (https=) |
| AU (1) | AU2019240274B2 (https=) |
| BR (1) | BR112020018981A8 (https=) |
| CA (1) | CA3093513A1 (https=) |
| IL (1) | IL277476B1 (https=) |
| IT (1) | IT201800003875A1 (https=) |
| MX (1) | MX2020009787A (https=) |
| SG (1) | SG11202008612XA (https=) |
| WO (1) | WO2019180658A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017135251A1 (ja) * | 2016-02-02 | 2017-08-10 | 国立研究開発法人物質・材料研究機構 | 強磁性トンネル接合体、これを用いた磁気抵抗効果素子及びスピントロニクスデバイス並びに強磁性トンネル接合体の製造方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025188676A1 (en) * | 2024-03-04 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of cells for secretion of therapeutic antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006018354D1 (de) * | 2005-12-05 | 2010-12-30 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| CA2638889C (en) * | 2006-02-06 | 2015-06-02 | Metheresis Translational Research S.A. | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| CN101914161B (zh) * | 2010-08-13 | 2013-12-11 | 四川大学 | 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途 |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
-
2018
- 2018-03-22 IT IT102018000003875A patent/IT201800003875A1/it unknown
-
2019
- 2019-03-21 SG SG11202008612XA patent/SG11202008612XA/en unknown
- 2019-03-21 US US16/982,330 patent/US11814433B2/en active Active
- 2019-03-21 MX MX2020009787A patent/MX2020009787A/es unknown
- 2019-03-21 JP JP2021500367A patent/JP7381555B2/ja active Active
- 2019-03-21 CA CA3093513A patent/CA3093513A1/en active Pending
- 2019-03-21 EP EP19721054.5A patent/EP3768710A1/en active Pending
- 2019-03-21 KR KR1020207030214A patent/KR20200135449A/ko not_active Ceased
- 2019-03-21 CN CN201980020753.XA patent/CN112041340A/zh active Pending
- 2019-03-21 BR BR112020018981A patent/BR112020018981A8/pt unknown
- 2019-03-21 WO PCT/IB2019/052307 patent/WO2019180658A1/en not_active Ceased
- 2019-03-21 AU AU2019240274A patent/AU2019240274B2/en active Active
-
2020
- 2020-09-21 IL IL277476A patent/IL277476B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE47860E1 (en) | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs | |
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| EP3353213B1 (en) | Anti-mesothelin antibody and composition comprising the same | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| ES2963561T3 (es) | Anticuerpo de unión a PSMA y usos del mismo | |
| US11623963B2 (en) | Cysteine engineered antigen-binding molecules | |
| JP2018512175A5 (https=) | ||
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2021518170A5 (https=) | ||
| WO2023109888A1 (zh) | 抗ang2-vegf双特异性抗体及其用途 | |
| JP2019511457A5 (https=) | ||
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2019180658A5 (https=) | ||
| JP2022504392A5 (https=) | ||
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| RU2020129465A (ru) | Комбинация антитела против hgfr и hegfr для лечения опухоли и/или метастаза | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| KR20260005269A (ko) | c-Met를 표적으로 하는 다중 특이성 항체 | |
| WO2026086844A1 (zh) | 靶向EGFR和c-Met的抗体药物偶联物 | |
| JP2026513451A (ja) | ｃ－Ｍｅｔを標的とする多重特異性抗体 | |
| WO2025108427A1 (zh) | 结合分子及抗体药物偶联物和用途 | |
| WO2026067489A1 (zh) | ITGβ6结合蛋白及其用途 | |
| HK40119169A (zh) | 配体-细胞毒性药物偶联物及其药物用途 | |
| HK40084724A (en) | Engineered anti-her2 bispecific proteins |